louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03757390: Bioequivalence Study of CJ-30060 in Healthy Volunteers
Official title: An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CJ-30060 in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Healthy Subjects
Lead sponsor: HK inno.N Corporation
Sponsor class: INDUSTRY
First posted: 2018-11-28
Enrollment: 52
Sex: ALL
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and Exforge® 5/160mg, Crestor® 10mg in healthy volunteers.

Detailed description: The purpose of this study is to compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and Exforge® 5/160mg, Crestor® 10mg in healthy volunteers.

Eligibility criteria: Inclusion Criteria:

* Healthy volunteers aged 20 to 45 years at screening
* BMI: 18\~29.9kg/㎡
* Body weight ≥50kg
* Subjects who decided to participate in the study and signed informed consent form voluntarily after receiving detailed explanation of the study and fully understanding

Exclusion Criteria:

* Subjects who had a medical history of severe cardiovascular, respiratory, hepatobiliary, renal, hematological, gastrointestinal, endocrinological, immunological, dermatological or neuropsychological disease
* Subjects who have symptoms of an acute disease within 28days before first administration
* Subjects who have clinically significant active, chronic disease
* Subjects who fall under the criteria below in laboratory test

  * AST/ALT \> UNL (upper normal limit) × 2
  * Total bilirubin \> UNL × 1.5
  * CrCL \< 50mL/min
  * CPK \> UNL × 2.5
* Subjects with clinically significant low blood pressure at screening test(systolic blood presure is less than 100mmHg or diastolic blood pressure is less than 60mmHg)
* Subjects with any positive reaction in HBsAg, anti-HCV Ab, anti HIV Ab, VDRL tests

Primary outcomes:
measure: Cmax of amlodipine
timeFrame: Up to 144 hours post-dose
measure: Cmax of valsartan
timeFrame: Up to 48 hours post-dose
measure: Cmax of rosuvastatin
timeFrame: Up to 72 hours post-dose
measure: AUClast of amlodipine
timeFrame: Up to 144 hours post-dose
measure: AUClast of valsartan
timeFrame: Up to 48 hours post-dose
measure: AUClast of rosuvastatin
timeFrame: Up to 72 hours post-dose
Secondary outcomes:
measure: AUCinf of amlodipine, valsartan, rosuvastatin
timeFrame: Up to 144 hours post-dose
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Korea University Anam Hospital
Study officials:
affiliation: Korea University Anam Hospital
name: Ji Young Park, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01282190: Effectiveness of Motivational Interview in Patients With Dyslipidemia
Official title: Effectiveness of Motivational Interview in Patients With Dyslipidemia Treated in Primary Care Consultations (Dislip-EM Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Patients With Dyslipidemia
Keywords: dyslipidemia, motivational interview, prevention
Lead sponsor: Hospital Universitario Reina Sofia de Cordoba
Sponsor class: OTHER_GOV
Collaborators: name: Spanish Society of Family and Community Medicine
First posted: 2011-01-24
Enrollment: 207
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Evaluate the effectiveness of motivational interviewing to improve lipid control and cardiovascular risk in patients with dyslipidemia.


Eligibility criteria: Inclusion Criteria:

* People diagnosed with dyslipidemia
* To sign informed consent.

Exclusion Criteria:

* Secondary hypercholesterolemia.
* Familial hypercholesterolemia.
* Deficiency syndromes family high density lipoprotein.
* Subjects with a history of cardiac or cerebrovascular events.
* Other chronic health problems such as diabetes or severe COPD.
* Subjects with current diagnosis of cancer.
* Patients with hepatic or renal disorders .
* Subjects heavy drinkers.
* Patients with long standing sick leave (more than 6 months).
* Pregnant or breastfeeding.

Primary outcomes:
measure: lipid levels
timeFrame: 12 months
Secondary outcomes:
measure: cardiovascular risk
timeFrame: 12 months
Other outcomes:
Locations:
city: Córdoba
country: Spain
facility: Family Medicine Teaching Unit and Community
Study officials:
References:
citation: Boveda-Fontan J, Barragan-Brun N, Campinez-Navarro M, Perula-de Torres LA, Bosch-Fontcuberta JM, Martin-Alvarez R, Arbonies-Ortiz JC, Novo-Rodriguez JM, Criado-Larumbe M, Fernandez-Garcia JA, Martin-Rioboo E; Collaborative Group Estudio Dislip-EM. Effectiveness of motivational interviewing in patients with dyslipidemia: a randomized cluster trial. BMC Fam Pract. 2015 Oct 24;16:151. doi: 10.1186/s12875-015-0370-2.
citation: Perula LA, Campinez M, Bosch JM, Barragan Brun N, Arbonies JC, Boveda Fontan J, Martin Alvarez R, Prados JA, Martin-Rioboo E, Massons J, Criado M, Fernandez JA, Parras JM, Ruiz-Moral R, Novo JM; collaborative Group Dislip-EM. Is the Scale for Measuring Motivational Interviewing Skills a valid and reliable instrument for measuring the primary care professionals motivational skills?: EVEM study protocol. BMC Fam Pract. 2012 Nov 22;13:112. doi: 10.1186/1471-2296-13-112.
citation: Perula LA, Bosch JM, Boveda J, Campinez M, Barragan N, Arbonies JC, Prados JA, Martin E, Martin R, Massons J, Criado M, Ruiz R, Fernandez JA, Buitrago F, Olaya I, Perez M, Ruiz J. Effectiveness of Motivational Interviewing in improving lipid level in patients with dyslipidemia assisted by general practitioners: Dislip-EM study protocol. BMC Fam Pract. 2011 Nov 5;12:125. doi: 10.1186/1471-2296-12-125.
Clinical trial NCT00552890: Modified Atkins Diet and Type 2 Diabetic Patients
Official title: Influende of a Modified Atkins Diet on Glucose Metabolism and Weight Loss in Obese Type 2 Diabetic Patients - A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obese Type 2 Diabetic Patients
Keywords: obesity
atkins
weight reduction
kidney function
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2007-11-02
Enrollment: 52
Sex: ALL
Minimum age (years): 35
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This randomized control trial compared the influence of an Atkins diet to that of the ADA recommended diet on Type 2 diabetic obese patients during a one-year follow-up period


Eligibility criteria: Inclusion Criteria:

* Type 2 diabetic patients age 35-75 years
* BMI 30-39.9kg/m
* HbA1C\>7%
* Not receiving insulin
* Micro-albumin excretion\<60 mg/day

Exclusion Criteria:

* Serum creatinine level \> 1.4 mg per deciliter
* Diastolic blood pressure \> 100 mmHg or systolic blood pressure \> 180mmHg
* Liver disease
* LDL cholesterol \> 160 mg per deciliter despite lipid-lowering treatment
* Use of psychiatric medications
* Osteoporosis
* Cancer
* Food allergies, and
* Low carbohydrate diet in the past 6 months.

Primary outcomes:
measure: weight loss and glucose control
timeFrame: 1 year
Secondary outcomes:
measure: lipid profile, kidney function
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
affiliation: Director, Diabetes Unit, Hadassah University Hospital
name: Itamar Raz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02920164: Auricular Acupuncture for Exam Anxiety in Medical Students
Official title: Auricular Acupuncture for Exam Anxiety in Medical Students: A Randomized Crossover Investigation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Anxiety
Lead sponsor: University Medicine Greifswald
Sponsor class: OTHER
First posted: 2016-09-30
Enrollment: 44
Sex: ALL
Minimum age (years): 19
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Title of the study: Auricular acupuncture (AA) for pre-exam anxiety: A blinded randomized crossover study on healthy volunteers

Study period: 04/2012 - 07/2012

Institution: Department of Anesthesiology and Intensive Care Medicine University Medicine of Greifswald

Aim of the study: To investigate the anxiolytic effect of auricular acupuncture (AA) in comparison to placebo acupuncture and no intervention during oral exams in anatomy at the University of Greifswald

Design: Prospective blinded randomized crossover trial

Intervention:

1. AA using indwelling fixed needles, retained 24 h in situ
2. AA using placebo needles

Number of volunteers: N = 40

Outcome measures: Anxiety level, Heart rate, blood pressure.


Eligibility criteria: Inclusion Criteria:

1. Medical students at the University of Greifswald
2. Going to take part in oral exams of human anatomy
3. Participants without previous anxiolytic medication
4. Participants without any experiences with acupuncture
5. Patients who have given written informed consent

Exclusion Criteria:

1. Local auricular skin infection
2. Pregnant or lactating women
3. Participants with prosthetic or damaged cardiac valves, intracardiac and intravascular shunts, hypertrophic cardiomyopathy and mitral valve prolapse (risk of bacterial endocarditis according to guidelines of AHA)
4. Participants who are unable to understand the consent form
5. History of psychiatric disease, alcohol and drug abuse

Primary outcomes:
measure: Intensity of anxiety
timeFrame: 2 days
Secondary outcomes:
measure: heart rate
timeFrame: 1 day
measure: blood pressure
timeFrame: 1 day
Other outcomes:
Locations:
city: Greifswald
country: Germany
facility: University Medicine of Greifswald
Study officials:
affiliation: University Medicine of Greifswald
name: Taras Usichenko, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT01044264: Clinical Study Between Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations
Official title: A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled Study Comparing Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations in the Treatment of Moderate to Severe Acne Vulgaris
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acne Vulgaris
Keywords: Acne Vulgaris
bioequivalency
clindamycin
benzoyl peroxide
Lead sponsor: Padagis LLC
Sponsor class: INDUSTRY
First posted: 2010-01-07
Enrollment: 602
Sex: ALL
Minimum age (years): 12
Maximum age (years): 40
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A randomized, double-blind, multiple-site, placebo-controlled, parallel-group clinical study conducted to evaluate the bioequivalence of two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel formulations.


Eligibility criteria: Inclusion Criteria:

* healthy men or women, 12 years of age and older
* willing to participate and sign a copy of the informed consent form
* moderate to severe facial acne

Exclusion Criteria:

* history of allergy or hypersensitivity to clindamycin or benzoyl peroxide
* pregnant or lactating women
* evidence of a clinically significant disorder
* receipt of any drugs as part of a research study within 30 days prior to study dosing
* use of systemic, topical or facial products which may interfere with study
* significant facial hair, tattoos, excessive facial scarring, active facial sunburn, or peeling due to sunburn

Primary outcomes:
measure: Reduction of Inflammatory Lesions
timeFrame: Baseline and week 11
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00257764: Behavioural Intervention for Dysphagia in Acute Stroke
Official title: A Randomised Controlled Trial of Dysphagia Therapies for Swallowing Disorders Following Stroke.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Dysphagia
Keywords: Swallowing disorder
Stroke
Standardized swallowing therapy
Randomized controlled trial
Lead sponsor: Royal Perth Hospital
Sponsor class: OTHER
Collaborators: name: Royal Perth Hospital Medical Research Foundation
First posted: 2005-11-23
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Swallowing dysfunction after stroke is common, but there is no reliable evidence for how it should be managed other than perhaps by nasogastric tube. This study compared the effectiveness of standardised, low and high intensity behavioral intervention for dysphagia with that of "usual care".

Detailed description: Stroke compromises swallowing function, causing dysphagia, in one quarter to one half of all patients. Dysphagia is associated with an increased risk of aspiration pneumonia, dehydration and malnutrition. Despite the development and implementation of several strategies of managing dysphagia after stroke, Few have been evaluated by means of randomised controlled trials.

Comparisons: This study aims to compare stroke patients with dysphagia assigned to receive usual swallowing care, prescribed by the attending physician; standardised low intensity intervention comprising swallowing compensation strategies and diet prescription; or standardised high intensity intervention and dietary prescription .

Eligibility criteria: Inclusion Criteria:

* clinical diagnosis of stroke within the previous 7 days
* clinical diagnosis of swallowing difficulty

Exclusion Criteria:

* no previous history of swallowing treatment
* no previous history of surgery of the head or neck

Primary outcomes:
measure: survival free of an abnormal diet at 6 months
Secondary outcomes:
measure: time to return to normal diet over the study
measure: recovery of swallowing ability at 6 months after stroke
measure: the occurrence of dysphagia - related medical complications at 6 months.
Other outcomes:
Locations:
city: Perth
country: Australia
facility: Royal Perth Hospital
state: Western Australia
Study officials:
affiliation: Royal Perth Hospital
name: Graeme Hankey, MBBS, MD,
role: STUDY_DIRECTOR
affiliation: Royal Perth Hospital
name: Giselle D Mann, MPH,PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Carnaby G, Hankey GJ, Pizzi J. Behavioural intervention for dysphagia in acute stroke: a randomised controlled trial. Lancet Neurol. 2006 Jan;5(1):31-7. doi: 10.1016/S1474-4422(05)70252-0.
Clinical trial NCT05474664: Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation
Official title: Phase 2 Open-label, Single-arm, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Camostat Mesylate in Patients with Protein-losing Enteropathy After Fontan Operation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Fontan Operation
Protein-Losing Enteropathy
Camostat Mesylate
Keywords: Fontan operation
Protein-Losing Enteropathy
Camostat mesylate
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2022-07-26
Enrollment: 19
Sex: ALL
Minimum age (years): 4
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is phase 2 open-label, single-arm, multi-center clinical trial to evaluate the efficacy and safety of Camostat mesylate in patients with Protein-losing enteropathy after Fontan operation.


Eligibility criteria: Inclusion Criteria:

* history of protein-losing enteropathy after Fontan operation

  * more than 6 months after Fontan operation
  * more than 3 months of protein-losing enteropathy history (ascites, edema, diarrhea, etc) and less than 3.0 mg/dL of serum albumin without evidence of renal or liver disease

Exclusion Criteria:

* inability to take oral camostate mesylate
* hypersensitivity to camostate mesylate
* patients with taking similar medication or prohibited combination drug
* patients participating in other clinical trials
* patients with diet limitation
* patients with genetic disease such as galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption

Primary outcomes:
measure: Serum albumin
timeFrame: 6 months
Secondary outcomes:
measure: Serum albumin
timeFrame: 6 months
measure: Stool alpha-1 antitrypsin
timeFrame: 6 months
measure: Stool alpha-1 antitrypsin
timeFrame: 6 months
measure: diarrhea
timeFrame: 6 months
measure: ascites
timeFrame: 6 months
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
state: Daehak-ro Jongno-gu
Study officials:
affiliation: Seoul National University Hospital
name: Gi Beom B Kim
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01725464: The Effect of Nasal Cannula During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy
Official title: The Effect of Nasal Cannula During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Lung Surgery
Hypoxia
Postoperative
Keywords: thoracotomy
oxygen saturation
postoperative
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2012-11-12
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: During early postoperative after lung resection surgery, patients without oxygen supplementation may experience hypoxemia. Oxygen supplementation can be given via oxygen mask or cannular. In this study the investigators want to the sudy the effect of oxygen supplementation via oxygen cannular during the first 120 minutes after surgery


Eligibility criteria: Inclusion Criteria:

* age =/\> 18 years
* lobectomy or pneumonectomy or wedge resection
* ASA 1-3
* preoperative oxygen saturation \< 95 %
* receiving epidural analgesia

Exclusion Criteria:

- cannot communication

Primary outcomes:
measure: Mean oxygen saturation at 30 minutes postoperative
timeFrame: 30 minutes
Secondary outcomes:
measure: incidence of oxygen saturation < 95% between 120 minutes until 3 days postoperative
timeFrame: 3 days
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Sirilak Suksompong
Study officials:
affiliation: Mahidol University
name: Sirilak Suksompong, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01729364: Fluid Investigation Colloid vs Crystalloid Reg. Renal Hemodynamics and Function
Official title: Colloid vs Crystalloid Infusion Postoperative in CABG Patients Regarding Renal Hemodynamics and Function
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Renal Impairment
Keywords: elective CABG
renal impairment
GFR
renal blood flow
colloid
crystalloid
thermodilution technique
oxygen supply demand
Lead sponsor: Sahlgrenska University Hospital
Sponsor class: OTHER
First posted: 2012-11-20
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Comparing the effects of crystalloid versus colloid fluid resuscitation in CABG patients postoperatively regarding renal blood flow, glomerular filtration rate and renal oxygen demand.

Detailed description: Due to blood loss and SIRS postoperative hypovolemia is a usual feature after CABG surgery. Substantial controversy persists regarding the best choice of fluid to be used for resuscitation in this setting regarding renal function and oxygen supply-demand matching. In our study we aim to investigate differences in functional renal parameters by dividing patients postoperatively in two groups, substituted either with crystalloid fluid, Ringer-Acetat, 20 ml/kg or colloid, HES 6% (130/0,4) 10 ml/kg under 20 minutes. Central and renal hemodynamics will be measured before (baseline) and after fluid administration by blood sampling and thermodilution in both pulmonary artery catheter and renal vein catheter. Measurement endpoints will mainly consist of central hemodynamics, renal blood flow, GFR and renal oxygen extraction rate which we aim to compare between groups.

Eligibility criteria: Inclusion Criteria:

* elective fast track CABG patients, postoperative

Exclusion Criteria:

* hemodynamic instability
* preoperative renal impairment
* major postoperative bleeding

Primary outcomes:
measure: Change from baseline and differences inbetween groups in glomerular filtration rate, measured at different timepoints
timeFrame: 125min after baseline-measures
Secondary outcomes:
Other outcomes:
Locations:
city: Göteborg
country: Sweden
facility: Sahlgrenska University Hospital/Thoracic Intensive Care
state: Västra Götaland
Study officials:
affiliation: Sahlgrenska University Hospital
name: Jenny Skytte Larsson, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Sahlgrenska University Hospital
name: Sven-Erik Ricksten, Professor
role: STUDY_CHAIR
References:
citation: Skytte Larsson J, Bragadottir G, Krumbholz V, Redfors B, Sellgren J, Ricksten SE. Effects of acute plasma volume expansion on renal perfusion, filtration, and oxygenation after cardiac surgery: a randomized study on crystalloid vs colloid. Br J Anaesth. 2015 Nov;115(5):736-42. doi: 10.1093/bja/aev346.
Clinical trial NCT06954064: The Student Living Lab: Intensive Longitudinal ESM Study for DP of ERFs to Stress in AYAs
Official title: Digital Phenotyping of Emotional Resilience Factors to Stress in Adolescents and Young Adults: a Longitudinal Ecological Approach
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Emotional Resilience
Lead sponsor: Babes-Bolyai University
Sponsor class: OTHER
Collaborators: name: The Executive Agency for Higher Education, Research, Development and Innovation Funding
First posted: 2025-05-01
Enrollment: 255
Sex: ALL
Minimum age (years): 10
Maximum age (years): 24
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: School- and university-aged students recruited from educational institutions in Cluj-Napoca.

Brief summary: This study aims at collecting continuous mobile-based devices data for determining emotional resilience factors and childhood abuse load profiles for stress and mental health problems.

Detailed description: Participants included in this study (age range = 10-24, G\*power estimated N = 255) will complete a set of questionnaires on constructs related to mental health and resilience, creating a digital phenotype based on individual profiles and investigating the dynamics between variables over a months' period.

Eligibility criteria: Inclusion Criteria:

* adolescents and young adults between 10 and 24 years old provided with written parental consent where applicable

Exclusion Criteria:

* intellectual disability or physical limitations precluded the use of the computer program

Primary outcomes:
measure: Resilience factors
timeFrame: One month, weekly (5 administrations)
measure: Mental Health
timeFrame: One month, weekly (5 administrations)
Secondary outcomes:
Other outcomes:
Locations:
city: Cluj-Napoca
country: Romania
facility: Babes-Bolyai University
state: Cluj
Study officials:
affiliation: Babes-Bolyai University
name: Oana A. David, Ph.D
role: PRINCIPAL_INVESTIGATOR
References: